Literature DB >> 18787063

Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications.

Nao Kinjo1, Hirofumi Kawanaka, Tomohiko Akahoshi, Shohei Yamaguchi, Daisuke Yoshida, Go Anegawa, Kozo Konishi, Morimasa Tomikawa, Kazuo Tanoue, Andrzej Tarnawski, Makoto Hashizume, Yoshihiko Maehara.   

Abstract

Portal hypertensive (PHT) gastric mucosa increases susceptibility to injury and delayed mucosal healing. It is possible that nitration of ERK by peroxynitrite might alter MAPK (ERK) signaling in PHT gastric mucosa, leading to delayed mucosal healing, since excessive nitric oxide production is implicated in PHT gastric mucosa and MAPK (ERK) signaling induces cell proliferation and leads to gastric mucosal healing in response to injury. Portal hypertension was produced by staged portal vein ligation, and sham-operation (SO) rats served as controls. Lipid peroxide (LPO) and nitrotyrosine increased significantly in PHT gastric mucosa compared with SO rats. ERK activation was impaired in PHT gastric mucosa in response to ethanol injury, whereas no significant difference in the phosphorylation of MEK, an upstream molecule of ERK, was seen between the two groups. The nitration of ERK by peroxynitrite, as detected by the coimmunoprecipitation of ERK and nitrotyrosine, was significantly enhanced in PHT gastric mucosa. Administration of rebamipide, a gastroprotective drug that acts as an oxygen-derived free radical scavenger, significantly decreased LPO and nitrotyrosine as well as the nitration of ERK by peroxynitrite in PHT gastric mucosa, therefore normalizing ERK activation and restoring the gastric mucosal healing response to ethanol injury. Enhanced nitration of ERK by peroxynitrite is involved in the impaired MAPK (ERK) signaling in PHT gastric mucosa. These findings demonstrate a new molecular mechanism in which PHT gastric mucosa is predisposed to injury and impaired healing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787063     DOI: 10.1152/ajpgi.90329.2008

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  7 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  Management of gastropathy and gastric vascular ectasia in portal hypertension.

Authors:  Cristina Ripoll; Guadalupe Garcia-Tsao
Journal:  Clin Liver Dis       Date:  2010-05       Impact factor: 6.126

3.  Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.

Authors:  Robert J Fontana; Arun J Sanyal; Marc G Ghany; Herbert L Bonkovsky; Timothy R Morgan; Heather J Litman; Andrea E Reid; William M Lee; Deepa Naishadham
Journal:  Am J Gastroenterol       Date:  2010-12-07       Impact factor: 10.864

4.  Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.

Authors:  Xue Han; Kui Jiang; Bangmao Wang; Lu Zhou; Xin Chen; Shu Li
Journal:  Clin Drug Investig       Date:  2015-10       Impact factor: 2.859

5.  Roles of oxidative stress in stomach disorders.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Hitoshi Tsugawa; Sachiko Mogami; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2011-12-09       Impact factor: 3.114

6.  Nitration-induced ubiquitination and degradation control quality of ERK1.

Authors:  Yuanya Zhang; Xiahe Huang; Jinlong Wang; Xiaorong Wang; Xiaofei Liu; Yuhang Chen; Wu Xu; Yingchun Wang
Journal:  Biochem J       Date:  2019-07-02       Impact factor: 3.857

7.  Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts.

Authors:  Yuki Nanke; Tsuyoshi Kobashigawa; Toru Yago; Manabu Kawamoto; Hisashi Yamanaka; Shigeru Kotake
Journal:  Biomed Res Int       Date:  2016-11-14       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.